Bristol-Myers Squibb Compnay

Jason M Guernon

Yong-Jin Wu

John E Macor

Kenneth M Boy

Jianliang Shi

Lorin A Thompson, Iii

Yunhui Zhang

Richard Eric Olson

Li Xu

Dmitry S Zuev

William John Pitts

Guanglin Luo

Carolyn Diane Dzierba

Amy C Hart

Sing-Yuen Sit

Steven H Spergel

Scott Hunter Watterson

Jie Chen

Junqing Guo

Lawrence R Marcin

Brian Lee Venables

Hua Gong

Zhizhen Barbara Zheng

Michael E Mertzman

Mendi A Higgins

Carolyn A Weigelt

Murugaiah Andappan Murugaiah Subbaiah

Lorin A Thompson Iii

Lorin A Iii Thompson

Iii Lorin A Thompson

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein. 

Aminoimidazopyridazines as kinase inhibitors

The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I) 

Acyl sulfonamide NaV1.7 inhibitors

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein Rand Rare independently hydrogen, or &#x2014;CH; or Rand Rcan join together in a ring by adding &#x2014;(CH)&#x2014;; Ris hydrogen or C-Calkyl; Y and Z are independently a C-C-aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, Calkylamino, Cdialkylamino, haloCalkyl, CN, C-Calkyl or cycloalkyl, C-Calkoxy, &#x2014;C&#x2550;OCalkyl, &#x2014;SOCalkyl, and C-Calkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, Calkylamino, Cdialkylamino, haloCalkyl, hydroxyCalkyl, CN, C-Calkyl or cycloalkyl, C-Calkoxy, and C-Calkynyl; L is &#x2014;NHCO&#x2014; or is a single bond; and L and Z together can be absent. 

4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production

The present disclosure provides a series of compounds of the formula (I) 

Compounds for the reduction of &#x3b2;-amyloid production

Compounds of the formula (I) are provided, including pharmaceutically acceptable salts thereof: which modulate &#x3b2;-amyloid peptide (&#x3b2;-AP) production, and are useful in the treatment of Alzheimer's Disease and other conditions affected by &#x3b2;-amyloid peptide (&#x3b2;-AP) production.

Compounds for the reduction of beta-amyloid production

The present disclosure provides a series of compounds of the formula (I) which reduce &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by &#x3b2;-amyloid peptide (&#x3b2;-AP) production.

Bicyclic compounds for the reduction of beta-amyloid production

Novel 2-arylthiazole derivatives of Formula I are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders that are responsive to the opening of the KCNQ potassium channels, including pain and migraine 

2-aryl thiazole derivatives as KCNQ modulators

Growing community of inventors

Moodus, CT, United States of America

Jason M Guernon